The Pharma & Healthcare industry is of vital importance for human and economic development, providing a wide range of goods and services relevant to the promotion of health at all stages in the healthcare process – from prevention and treatment to rehabilitation and palliative care. It is one of the fastest-growing industries, supported by profound demographic changes, the rising incidence of non-communicable diseases, and surging per capita health spending in both developed and emerging markets. The industry is also one of the major innovators, with increasing expenditures on development of new molecules, biotechnology and adoption of new technologies that provide advanced healthcare and ensure the longevity of the population.
The Pharma & Healthcare industry comprises the manufacture of pharmaceuticals for human and veterinary use, medical equipment and related supplies. It also includes providers of ambulatory health services, medical and diagnostic laboratories, hospitals, and nursing and residential care facilities.
China's healthcare system is hospital-centric, with public hospitals delivering approximately 90% of the inpatient and outpatient care consumed in the country in both hospitals and basic medical institutions. Nearly 40% of hospitals’ revenue is ...View more details
The Philippines healthcare and pharmaceuticals sector has grown gradually in past years due to the country’s population and economic growth. Recently, sector growth has accelerated due to policy measures to increase the healthcare budget which ...View more details
Indonesia's healthcare and pharmaceuticals industry is one of the least developed in ASEAN and Indonesia has low scores on most metrics – including number of hospitals and beds per 10,000 population and healthcare expenditure per capita. These ...View more details
The Malaysian healthcare and pharmaceuticals sector has been growing strongly as a result of factors including one of the highest population growth rates in the ASEAN region, increasing affluence, and growing access to healthcare funding. In ...View more details
Thailand is the second-largest pharmaceutical market in South East Asia, with sales of THB 152.9bn in 2015. The pharmaceutical industry specialises in generic drug production and this is the largest segment on the market. Spending on health is ...View more details
In 2015, the total Hungarian healthcare expenditure amounted to HUF 2,373.4bn, or 7.04% of GDP. Public financing schemes made up 67.1% of the healthcare spending. By regional standards, the Hungarian health spending as a percentage of GDP is high, ...View more details
China's healthcare system is hospital-centric, with public hospitals delivering approximately 90% of the inpatient and outpatient care consumed in the country today in both hospitals and basic medical institutions*. Nearly 40% of hospitals’ ...View more details
In 2015, Chile was the sixth largest pharmaceutical market in Latin America in terms of sales volume, with 278mn units sold, and the seventh biggest in terms of sales value, with USD 1.53bn, based on ex-factory prices (USD 2.32bn, based on retail ...View more details
The Russian healthcare and pharmaceutical sector is suffering under the impact of ongoing recession in the Russian economy and depressed domestic demand. The healthcare system is in dire need of financing as lower oil prices and a sharply devalued ...View more details
The Czech pharmaceutical sector is very attractive for international pharmaceutical manufacturers due to the favourable cost-efficiency ratio. The pharmaceutical sector generated a GVA of CZK 17.9bn in 2015, accounting for 0.4% of the total GVA. ...View more details